Replies to post #225336 on Biotech Values

[DewDiligence]

ABUS partially monetizes Onpattro royalty stream for $20M:

https://www.globenewswire.com/news-release/2019/07/02/1877562/0/en/Arbutus-Sells-Part-of-its-ONPATTRO-patisiran-Royalty-Interest-to-OMERS.html

Under the terms of the LNP license agreement with Alnylam for Onpattro, Arbutus is entitled to tiered royalty payments on net sales of Onpattro ranging from 1.00% - 2.33% after offsets, with the highest tier applicable to annual net sales above $500M. This royalty interest has been sold to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of the entitlement will revert to Arbutus.

In addition to this royalty from the Alnylam LNP license agreement, Arbutus is also entitled to a second, but lower, royalty interest on net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics. The royalty from Acuitas has been maintained by Arbutus and is not part of the royalty sale to OMERS.